Fig. 2From: Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trialIndividual time response curves for the AUC of the 5-min course of the FMD between randomization, 8Â weeks, and 16Â weeksBack to article page